Valuation: BLS Pharmaceuticals Limited

Market Cap 213M 151M 131M 123M 112M 210M 14.48B 1.44B 565M 7.24B 568M 555M 24.13B P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 207M 147M 127M 119M 108M 204M 14.07B 1.4B 548M 7.04B 551M 539M 23.43B EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
45.27%
Yield 2024 *
-
Yield 2025 -
1 day-0.53%
1 week+1.09%
Current month+14.81%
1 month+7.51%
3 months+12.05%
6 months+102.17%
Current year+121.43%
1 week 0.9
Extreme 0.9
0.95
1 month 0.78
Extreme 0.775
0.95
Current year 0.36
Extreme 0.36
1.1
1 year 0.33
Extreme 0.33
1.1
3 years 0.04
Extreme 0.04
1.1
5 years 0.04
Extreme 0.04
1.1
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Date Insider Type Main position Quantity % Market Cap.
12/23/25 A Free

Chief Operating Officer

10,000,000 0.4567%
12/23/25 A Free

Chief Executive Officer

20,000,000 0.9133%
12/23/25 A Free

Chief Executive Officer

39,000,000 1.7810%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%+1.09%+75.47%+481.25% 153M
-0.11%-1.67%+1.80%+19.90% 48.84B
+0.97%+3.95%+486.20%+621.37% 45.44B
+1.45%+2.36%+15.16%+90.49% 41.22B
+0.42%-0.63%+25.85%+13.24% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+2.06%-0.82% - - 16.25B
-1.40%-2.52%+27.51%+136.40% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-1.65%+0.24%+80.08%+42.13% 13.68B
Average -0.20%-0.54%+81.42%+165.56% 26.86B
Weighted average by Cap. +0.04%-0.84%+103.05%+153.03%

Financials

2024 2025
Net sales 9.64M 6.84M 5.91M 5.56M 5.05M 9.5M 655M 65.21M 25.56M 328M 25.68M 25.13M 1.09B 29.28M 20.77M 17.94M 16.88M 15.34M 28.86M 1.99B 198M 77.6M 995M 77.99M 76.3M 3.32B
Net income -13.33M -9.45M -8.17M -7.68M -6.98M -13.13M -906M -90.12M -35.32M -453M -35.49M -34.72M -1.51B 4.9M 3.48M 3M 2.83M 2.57M 4.83M 333M 33.15M 12.99M 167M 13.06M 12.77M 555M
Net Debt -318K -225K -195K -183K -166K -313K -21.59M -2.15M -842K -10.8M -846K -828K -35.96M -6.13M -4.35M -3.76M -3.54M -3.21M -6.05M -417M -41.48M -16.26M -209M -16.34M -15.98M -695M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
18/08/26 A$0.9300 -0.53% 130,266
17/08/26 A$0.9350 -0.53% 255,039
14/08/26 A$0.9400 -0.53% 157,001
13/08/26 A$0.9450 +1.61% 187,252
12/08/26 A$0.9300 +3.33% 143,092

Annual profits - Rate of surprise